

BIOGRAPHICAL SKETCH

NAME Sudhir Srivastava, Ph.D., MPH, MS (Computer Science)	POSITION TITLE Chief, Cancer Biomarkers Research Group		
CURRENT AFFILIATION National Cancer Institute, National Institutes of Health, Bethesda, MD			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Banaras Hindu University	Ph.D.,	1977	Biological Sciences: Biomechanical Changes in Rats During Aging – Myosin ATPase, CPK and Actin
Virginia Commonwealth University	MS	1987	Computer Science
Johns Hopkins University, School of Medicine	MPH	1997	Master of Public Health

List of five recent publications by the candidate:

Feng Z, Kagan J, Srivastava S. Toward a Robust System for Biomarker Triage and Validations – EDRN Experience. Chapter 21, In Prostate Cancer Screening, 2nd edition. eds. DP Ankerst, C Tangen, IM Thompson. 2009. Human Press.

Harsha HC, Kandasamy K, Rangnathan P,...Srivastava S,...Pandey A (2009) A Compendium of Potential Biomarkers of Pancreatic Cancer, PLoS 6(4): 1-6

Srivastava S (2008) Biomarkers At A Crossroads: Implications for Early Cancer Detection & Diagnosis, IARC World Cancer Report, in press

Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, Diamandis EP, Escott N, Skehan A, Prowse O, Thayer RE, Froberg MK, Wilson MJ, Maragh S, Jakupciak JP, Wagner PD, Srivastava S, Dakubo GD, Parr RL (2008). Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol. Jan;129(1):57-66

Samantha Maragh, John P Jakupciak, Paul D Wagner, William N Rom, David Sidransky, Sudhir Srivastava and Catherine D O'Connell (2008) Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Medical Genetics 9: 1-9

Please indicate in 200 words or less the reason(s) why you would be a suitable candidate for the HUPO Council elections.

Dr. Srivastava has received several honors and awards and is a member of several scientific committees (AJCC, AACR, All Ireland-NCI Consortium). Dr. Srivastava is a founding member of HUPO and has since actively participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives. He is the principal architect of the NCI's Early Detection Research Network and Alliance of Glycobiologists for the Detection of Cancer and Cancer Risk, which has supported several HUPO Initiatives on plasma proteome (led by Gil Omen) and glycomics (led by Taniguchi). He supported the first-ever joint meetings of EDRN-HUPO PPP and Proteomics Jamboree, and recently-held the US-Japan meeting on Glycolic. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. Recently, he has edited two books: **Early Detection of Cancer: Molecular Markers and Molecular Pathology of Early Cancer**. He is also the Editor-in Chief of **Disease Markers** and **Cancer Biomarkers**. Recently, he edited a book on **Informatics in Proteomic**. If elected to the HUPO Council, Dr. Srivastava will

continue to work to strengthen clinical, epidemiological and health care perspectives of proteomics and forge partnerships with public and private sectors. Dr. Srivastava has focused his entire professional career on programs in genomics, proteomics, epigenomics, and metabolomics, all of which are the focus of HUPO. He brings public health perspectives to the mission of HUPO in regard to proteomics in cancer screening, early detection, risk assessment and informatics.